Share ownership Zealand Pharma A/S

ZEAL

DK0060257814

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2026-06-04 am EDT			5-day change	1st Jan Change
326.30 ^DKK	+9.02%		+0.43%	-30.04%

Jun. 05	Zealand touts promising tolerability data for obesity drug in mid-stage study	RE
Jun. 05	Zealand Pharma A/S Presents Additional Data From Phase 2 ZUPREME-1 Trial Evaluating Petrelintide At The American Diabetes Association 2026 Scientific Sessions	CI

Share class: Zealand Pharma A/S

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	71,525,575	70,279,737 ( 98.26 %)	865,485 ( 1.21 %)	98.26 %

Major shareholders: Zealand Pharma A/S

Name	Equities	%	Valuation
Van Herk Investments BV 9.998 %	7,151,045	9.998 %	336 M kr
ZEALAND PHARMA A/S 1.269 %	907,905	1.269 %	43 M kr
Nykredit Bank A/S (Investment Management) 0.8062 %	576,608	0.8062 %	27 M kr
Goldman Sachs Asset Management International 0.3633 %	259,860	0.3633 %	12 M kr
DNB Carnegie Investment Bank AB (Investment Management) 0.2416 %	172,776	0.2416 %	8 M kr
Mackenzie Investments Europe Ltd. 0.2191 %	156,702	0.2191 %	7 M kr
Adam Sinding Steensberg 0.2007 %	143,559	0.2007 %	7 M kr
Invesco Management S.A. (Germany) 0.1775 %	126,936	0.1775 %	6 M kr
Apo Asset Management GmbH 0.1669 %	119,347	0.1669 %	6 M kr
Svenska Handelsbanken AB (Denmark) 0.1113 %	79,636	0.1113 %	4 M kr
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	12.68%
Zealand Pharma A/S	1.27%
Individuals	0.54%
Unknown	85.51%

Based on 1000 largest holdings

Geographical origin of shareholders

Netherlands	10%
Denmark	2.59%
Individuals	0.54%
United Kingdom	0.49%
Germany	0.43%
Ireland	0.23%
Spain	0.07%
Norway	0.05%
Luxembourg	0.03%
Switzerland	0.02%
France	0.01%
Finland	0.01%
Australia	0.01%

Based on 1000 largest holdings

Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity. At the end of 2025, the Group had a portfolio of 8 products in clinical development (including 3 in phase III, 3 in phase II and 2 in phase I), and 1 product in preclinical development.

Employees

544

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company